KK8398

KK8398 is an **oral small molecule inhibitor targeting FGFR3 (fibroblast growth factor receptor 3)**, being developed primarily for the treatment of **achondroplasia**, a genetic disorder characterized by impaired bone growth and short stature. The drug is being studied for its ability to increase annualized height velocity in pediatric patients with achondroplasia, with a major Phase 3 clinical trial underway to evaluate its long-term efficacy and safety. The compound is developed and studied by Kyowa Kirin, and is also associated with QED Therapeutics as a licensing partner. The clinical strategy focuses on modifying abnormal FGFR3 signaling, which is a central pathogenic mechanism in achondroplasia[1][3][7].